# US 11,433,006 B2 · Methods, compositions, and delivery systems for therapeutic skin treatments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,006 B2
- Document ID: US11433006B2
- Status: Granted
- Kind: B2
- Application number: 16/800,015
- Filed: 2020-02-25
- Published: 2020-08-27
- Granted: 2022-09-06
- Earliest claimed: 2019-02-25
- Assignees: Topix Pharmaceuticals, Inc.
- Applicants: Topix Pharmaceuticals, Inc.
- Inventors: Steven M. Hernandez
- Web page: https://patentgrep.com/patent/US11433006B2

## CPC

- A61K 8/0212: {Face masks}
- A61B 17/32093: {for skin incisions}
- A61K 8/347: {Phenols}
- A61K 8/4946: {Imidazoles or their condensed derivatives, e.g. benzimidazoles}
- A61K 8/4953: {containing pyrimidine ring derivatives, e.g. minoxidil}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/731: {Cellulose; Quaternized cellulose derivatives}
- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 8/9789: Magnoliopsida [dicotyledons]
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K 36/30: Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
- A61K 36/42: Cucurbitaceae (Cucumber family)
- A61K 36/47: Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A61K 36/82: Theaceae (Tea family), e.g. camellia
- A61K 36/896: Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61Q 19/007: {Preparations for dry skin}
- A61Q 19/08: Anti-ageing preparations
- A61B 2017/00747: {Dermatology}
- A61K 2800/522: Antioxidants; Radical scavengers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Disclosed are skincare formulations, delivery systems and treatment methods containing an oligopeptide and a combination of antioxidants for topical application to the skin before and/or after dermatological procedures that affect the skin's barrier. The systems herein alleviate discomfort and enable rapid healing of irritated and damaged skin, and provide improved treatment outcomes for dermatological procedures. The disclosed topical formulations, delivery systems, and methods thereof provide enhanced penetration of the active ingredients to the skin while maintaining skin moisture and protecting sensitive skin after dermatological procedures for improvement of aesthetic skin properties. Also provided are methods for therapeutic treatment of dermatological conditions by topically applying, using, for example, a pre-moistened bio-cellulose mask, a formulation comprising (% w/w) at least 0.0001% palmitoyl sh-tripeptide-4 amide on an active basis and at least 0.1% Camellia sinensis leaf extract.

## Claims

### Claim 1

A topical formulation for therapeutic treatment of skin in dermatological procedures, comprising (% w/w)
0.001%-10% sodium hyaluronate,
an oligopeptide, wherein the oligopeptide is 0.0001%-10% palmitoyl sh-tripeptide-4 amide on an active basis,
one or more antioxidants, wherein the one or more antioxidants is between 0.1%-10% w/w and comprises one or more of Camellia sinensis leaf extract, resveratrol, ectoin, Cucumis satvius fruit extract, ergothioneine, Phyllanthus emblica fruit extract,
10%-99% purified water;
0.001%-75% hydrolyzed sodium hyaluronate;
0.001%-99% Camellia sinensis leaf extract;
0.001%-5.0% resveratrol;
0.001%-5% ectoin;
0.001%-5% ergothioneine;
0.001%-5% bisabolol;
0.001%-99% Cucumis satvius fruit extract;
0.001%-99% sodium pyrrolidone carboxylic acid (PCA);
0.001%-99% Chamomila recutita flower extract;
0.001%-99% comfrey extract;
0.001%-99% yucca glauca root extract;
0.001%-5% Phyllanthus emblica fruit extract;
0.001%-5% caffeine;
0%-2% sodium phosphate;
0%-0.5% potassium hydroxide;
0.0%-3.5% phenylcarbinol;
0.0%-0.5% sodium benzoate;
0.0%-0.3% disodium Ethylenediaminetetraacetic acid (EDTA); and
0.01%-10% polysorbate 20.

### Claim 2 (depends on 1)

The formulation of claim 1, comprising (% w/w):
82.41% purified water;
1.00% hydrolyzed sodium hyaluronate;
0.10% sodium hyaluronate;
0.01% Camellia sinensis leaf extract;
0.01% resveratrol;
4.00% palmitoyl sh-tripeptide-4 amide;
0.01% ectoin;
0.01% ergothioneine;
0.20% bisabolol;
0.01% Cucumis satvius fruit extract;
0.01% sodium pyrrolidone carboxylic acid (PCA);
0.01% Chamomila recutita flower extract;
0.01% comfrey extract (Symphytum officinale leaf extract, Leuconostoc/radish root ferment filtrate);
0.01% yucca glauca root extract;
0.10% Phyllanthus emblica fruit extract;
0.01% caffeine;
0.638% sodium phosphate;
0.226% potassium hydroxide;
0.20% phenylcarbinol;
0.05% sodium benzoate;
0.05% disodium Ethylenediaminetetraacetic acid (EDTA); and
0.70% polysorbate 20.

### Claim 3 (depends on 1)

A sheet for therapeutic treatment of skin in dermatological procedures, comprising the sheet structured for topical application to skin selected for a dermatological procedure, the sheet being pre-moistened with a therapeutically effective amount of a formulation of claim 1.

### Claim 4 (depends on 3)

The sheet of claim 3, wherein the sheet is a biocellulose sheet and is structured as a facial mask.

### Claim 5 (depends on 3)

The sheet of claim 3, wherein the formulation and/or sheet pre-moistened with the formulation is sterilized.

### Claim 6 (depends on 1)

The topical formulation of claim 1, wherein the formulation is sterile.

### Claim 7 (depends on 1)

The topical formulation of claim 1, wherein the formulation is a sheet.